<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123861</url>
  </required_header>
  <id_info>
    <org_study_id>16-3392</org_study_id>
    <nct_id>NCT03123861</nct_id>
  </id_info>
  <brief_title>Gabapentin for Postop Pain After SSLF</brief_title>
  <official_title>Randomized Controlled Trial of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To assess the impact of gabapentin versus placebo on overall postoperative pain and&#xD;
      gluteal pain at 7 days after vaginal sacrospinous ligament suspension for apical pelvic organ&#xD;
      prolapse.&#xD;
&#xD;
      Participants: English-speaking women planning to undergo a vaginal SSLF. Concurrent&#xD;
      procedures can be performed except total vaginal hysterectomy, colpocleisis, anal&#xD;
      sphincteroplasty, fistula surgery, or urethral diverticulectomy&#xD;
&#xD;
      Procedures (methods): Patients will be randomized to receive either 2 weeks of gabapentin or&#xD;
      placebo for 2 weeks post-operatively. Standard of care pain medications will be given to both&#xD;
      groups. Patients will be followed for 6 weeks post-operatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic organ prolapse (POP), the herniation of the bladder, uterus, or rectum, into and often&#xD;
      beyond, the vaginal opening, affects 40% of postmenopausal women and significantly impairs&#xD;
      quality of life. POP is often managed surgically, and currently, one in every eight women&#xD;
      will undergo POP surgery during her lifetime.&#xD;
&#xD;
      A commonly performed procedure for POP is a sacrospinous ligament fixation (SSLF), which is a&#xD;
      vaginal surgery that involves suspending the vaginal apex to the sacrospinous ligament&#xD;
      suspension with sutures. Beyond routine postoperative pain, a sacrospinous ligament fixation&#xD;
      may result in significant gluteal pain as a result of the vaginal sutures affecting/impinging&#xD;
      on the sacral nerve roots. Unfortunately, postoperative gluteal pain is not uncommon with 12%&#xD;
      of patients reporting significant gluteal pain and 4% having persistent pain 6 weeks after&#xD;
      surgery.&#xD;
&#xD;
      This study aims to compare the impact of gabapentin versus placebo on postoperative pain&#xD;
      after SSLF. The rationale is that studies have shown that preoperative gabapentin, a&#xD;
      non-opioid analgesic, resulted in a lower narcotic use postoperatively. Decreasing the use of&#xD;
      standard of care postoperative narcotic pain medications would also decrease adverse events&#xD;
      due to narcotics such as nausea, vomiting, and constipation, and potentially decrease the&#xD;
      long-term risk of opioid dependence. As an additional benefit, a careful assessment of actual&#xD;
      opioid will help to inform best practices for prescribing, as we may be overprescribing&#xD;
      narcotic medications for this type of surgery. This study will evaluate a longer two-week&#xD;
      course of gabapentin because it is currently standard of care to use gabapentin to treat&#xD;
      neuropathic pain after SSLF; thus, gabapentin may help to address overall pain as well as&#xD;
      neuropathic gluteal pain that can occur after SSLF. Furthermore, gabapentin is a relatively&#xD;
      safe medication with the primary adverse events being dizziness and sedation.&#xD;
&#xD;
      Given the risk of overall postoperative pain and neuropathic gluteal pain after a&#xD;
      sacrospinous ligament fixation for POP and the evidence that perioperative gabapentin may&#xD;
      decrease acute pain and neuropathic pain, this study proposes a novel randomized trial to&#xD;
      compare perioperative gabapentin versus placebo on postoperative pain after a vaginal SSLF&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">July 25, 2020</completion_date>
  <primary_completion_date type="Actual">July 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain During Normal Activities (Surgical Pain Scale Item 2)</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Post-operative pain at week 1 will be measured by item 2 of the surgical pain scale (SPS). This item asks for the average amount of pain felt during normal activity in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gluteal Pain During Normal Activities</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Gluteal post-op pain will be measured by an item similar to that used for the primary outcome which asks for the average amount of gluteal pain felt during normal activity in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Pain (Surgical Pain Scale Item 4)</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Post-operative pain will be measured by item 4 of the surgical pain scale (SPS). This item asks for how unpleasant or disturbing the worst pain was in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Narcotic Use</measure>
    <time_frame>First 14 days after surgery</time_frame>
    <description>Median daily post-op narcotic pain medication in morphine milliequivalents per day during the first 14 days after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo for the 2 weeks after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women age 18+&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Planning to undergo a vaginal SSLF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or planning to become pregnant during study participation&#xD;
&#xD;
          -  Prior vaginal mesh surgery for pelvic organ prolapse&#xD;
&#xD;
          -  Planning a concurrent total vaginal hysterectomy, colpocleisis (total vaginectomy or&#xD;
             LeFort colpocleisis), mesh excision, anal sphincteroplasty, fistula repair, or&#xD;
             urethral diverticulectomy&#xD;
&#xD;
          -  Cognitive impairment (indicated by a score of 0-2 on Mini-Cog)&#xD;
&#xD;
          -  Currently taking gabapentin or pregabalin (Lyrica) or previous intolerance to&#xD;
             gabapentin or pregabalin&#xD;
&#xD;
          -  Daily use of narcotics for â‰¥ 2 months&#xD;
&#xD;
          -  Acute or chronic renal failure based on past medical history (PMH) or glomerular&#xD;
             filtration rate (GFR) &lt; 30ml/min (see meds info below)&#xD;
&#xD;
          -  Severe uncontrolled depression or bipolar disease based on PMH&#xD;
&#xD;
          -  Fall risk if history of fall in last year or current use of cane/walker&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Wu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <results_first_submitted>September 30, 2020</results_first_submitted>
  <results_first_submitted_qc>September 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2020</results_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvic Organ Prolapse</keyword>
  <keyword>postoperative gluteal pain</keyword>
  <keyword>opioid use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03123861/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Oral Capsule</title>
          <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Oral Capsule</title>
          <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="7.8"/>
                    <measurement group_id="B2" value="61.2" spread="13.7"/>
                    <measurement group_id="B3" value="62.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg / m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="4.6"/>
                    <measurement group_id="B2" value="28.1" spread="4.1"/>
                    <measurement group_id="B3" value="28.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain During Normal Activities (Surgical Pain Scale Item 2)</title>
        <description>Post-operative pain at week 1 will be measured by item 2 of the surgical pain scale (SPS). This item asks for the average amount of pain felt during normal activity in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain.</description>
        <time_frame>7 days after surgery</time_frame>
        <population>Participants who underwent sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
          </group>
        </group_list>
        <measure>
          <title>Pain During Normal Activities (Surgical Pain Scale Item 2)</title>
          <description>Post-operative pain at week 1 will be measured by item 2 of the surgical pain scale (SPS). This item asks for the average amount of pain felt during normal activity in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain.</description>
          <population>Participants who underwent sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.5"/>
                    <measurement group_id="O2" value="3.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gluteal Pain During Normal Activities</title>
        <description>Gluteal post-op pain will be measured by an item similar to that used for the primary outcome which asks for the average amount of gluteal pain felt during normal activity in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain.</description>
        <time_frame>7 days after surgery</time_frame>
        <population>Participants who underwent a sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
          </group>
        </group_list>
        <measure>
          <title>Gluteal Pain During Normal Activities</title>
          <description>Gluteal post-op pain will be measured by an item similar to that used for the primary outcome which asks for the average amount of gluteal pain felt during normal activity in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain.</description>
          <population>Participants who underwent a sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.0"/>
                    <measurement group_id="O2" value="3.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Pain (Surgical Pain Scale Item 4)</title>
        <description>Post-operative pain will be measured by item 4 of the surgical pain scale (SPS). This item asks for how unpleasant or disturbing the worst pain was in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain</description>
        <time_frame>7 days after surgery</time_frame>
        <population>Participants who underwent sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Pain (Surgical Pain Scale Item 4)</title>
          <description>Post-operative pain will be measured by item 4 of the surgical pain scale (SPS). This item asks for how unpleasant or disturbing the worst pain was in the last 24 hours on a scale of 1-10 with 10 representing the most intense/worst pain</description>
          <population>Participants who underwent sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.4"/>
                    <measurement group_id="O2" value="4.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Narcotic Use</title>
        <description>Median daily post-op narcotic pain medication in morphine milliequivalents per day during the first 14 days after surgery</description>
        <time_frame>First 14 days after surgery</time_frame>
        <population>Participants who underwent sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Narcotic Use</title>
          <description>Median daily post-op narcotic pain medication in morphine milliequivalents per day during the first 14 days after surgery</description>
          <population>Participants who underwent sacrospinous ligament fixation surgery with follow-up data 7 days after surgery</population>
          <units>morphine milliequivalents per day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.5" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.4" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the day of surgery until the 6-week postoperative visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.&#xD;
Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Oral Capsule</title>
          <description>Participants will take placebo for the 2 weeks after surgery.&#xD;
Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Wu, MD, MPH, Professor of OBGYN</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-0014</phone>
      <email>jennifer_wu@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

